EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorEisbach Bio GmbH
About this trial
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
Eligibility criteria
Qualifiers
Recurrent locally advanced or metastatic solid tumors
Homologous recombination deficient mutations
Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy
Measurable disease (RECIST 1.1 Criteria)
Disqualifiers
History or evidence of any clinically relevant gastrointestinal disease
Radiation therapy within ≤2 weeks
Significant cardiovascular disease
Uncontrolled, active, symptomatic brain metastases
Trial design
Treatments tested in this trial
- EIS-12656
- Olaparib
- Trastuzumab deruxtecan
Treatment groups
144 Participants
are divided into 4 treatment groupsLocations
1MD Anderson Cancer Center77030, HoustonTexas, United States
Sponsors and collaborators
Eisbach Bio GmbH
Lead sponsor
Source ClinicalTrials.gov